<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">12349956</PMID>
        <DateCreated>
            <Year>2002</Year>
            <Month>09</Month>
            <Day>27</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2003</Year>
            <Month>03</Month>
            <Day>18</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1567-5769</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>2</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2002</Year>
                        <Month>Jul</Month>
                    </PubDate>
                </JournalIssue>
                <Title>International immunopharmacology</Title>
                <ISOAbbreviation>Int. Immunopharmacol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Inhibitory effects of relaxin on human basophils activated by stimulation of the Fc epsilon receptor. The role of nitric oxide.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1195-204</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>This study investigates whether relaxin (RLX), a hormone previously shown to inhibit mast cell function and to stimulate endogenous nitric oxide (NO) biosynthesis, counteracts the activation of isolated human basophils stimulated with anti-IgE or phorbol ester, and, if so, whether NO is involved. RLX reduced dose-dependently the expression of the activation marker CD63, the release of histamine and the rise of intracellular Ca2+ levels which triggers granule release by stimulated basophils. RLX also blunts the ultrastructural signs of anaphylactic granule release. The effects of RLX appear to depend upon activation of Ca2+/calmodulin-dependent NO synthase and endogenous NO production. They were reproduced by the NO donor sodium nitroprusside (SNP) and were reverted by the NO synthase inhibitor N(omega)-monomethyl-L-arginine, or by the NO scavenger oxyhemoglobin, or by blocking the NO physiological target guanylate cyclase with ODQ. In conclusion, RLX appears to play a role in down-regulating basophil function upon immunologic and nonimmunologic activation.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Bani</LastName>
                    <ForeName>Daniele</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>Department of Anatomy, Histology and Forensic Medicine, University of Florence, Italy. daniele.bani@unifi.it</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Baronti</LastName>
                    <ForeName>Roberto</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vannacci</LastName>
                    <ForeName>Alfredo</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bigazzi</LastName>
                    <ForeName>Mario</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sacchi</LastName>
                    <ForeName>Tatiana Bani</ForeName>
                    <Initials>TB</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mannaioni</LastName>
                    <ForeName>Pier Francesco</ForeName>
                    <Initials>PF</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Masini</LastName>
                    <ForeName>Emanuela</ForeName>
                    <Initials>E</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>Int Immunopharmacol</MedlineTA>
            <NlmUniqueID>100965259</NlmUniqueID>
            <ISSNLinking>1567-5769</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Receptors, IgE</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>31C4KY9ESH</RegistryNumber>
                <NameOfSubstance>Nitric Oxide</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9002-69-1</RegistryNumber>
                <NameOfSubstance>Relaxin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Basophils</DescriptorName>
                <QualifierName MajorTopicYN="Y">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
                <QualifierName MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Nitric Oxide</DescriptorName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
                <QualifierName MajorTopicYN="Y">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Receptors, IgE</DescriptorName>
                <QualifierName MajorTopicYN="Y">biosynthesis</QualifierName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Relaxin</DescriptorName>
                <QualifierName MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2002</Year>
                <Month>9</Month>
                <Day>28</Day>
                <Hour>4</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2003</Year>
                <Month>3</Month>
                <Day>19</Day>
                <Hour>4</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2002</Year>
                <Month>9</Month>
                <Day>28</Day>
                <Hour>4</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">12349956</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
